Latest / The Psychology Undergrad Podcast / Agonist vs Antagonist: Pharmacodynamics & How Drugs Act on Receptors
Transcript
- 0:00Welcome to the Psychology Undergrad. I'm so glad
- 0:02you could join us for this study session today.
- 0:04Yeah, it is going to be a really good one. It
- 0:06is. We are doing a deep dive into our chapter
- 0:08six source material, which is all about pharmacodynamics.
- 0:13And before we get into the actual biology of
- 0:16it all, I think we have to address this massive
- 0:19misconception that Basically everyone has. Oh
- 0:22for sure. Because you know think about the last
- 0:25time you saw someone act completely out of character
- 0:27on a substance. It is so tempting to look at
- 0:31that and think Well, the drug just possessed
- 0:33them. Right. Like they're under a magic spell
- 0:35or something. Exactly. Like it has some sort
- 0:37of external demon or that the drug magically
- 0:39invented a brand new behavior out of thin air.
- 0:42But the notes lay out this fundamental, unbreakable
- 0:45rule in biology that just completely shatters
- 0:48that illusion. It really does. Drugs literally
- 0:50cannot make your body do anything it doesn't
- 0:52already normally do. Which is such a wild paradigm
- 0:55shift when you first hear it. It really is. Because
- 0:57a drug doesn't... you know, invent a new physiological
- 1:00function. You can only change the rate of pre
- 1:03-existing processes. And since the rate of literally
- 1:07every bodily function is controlled by neurotransmission,
- 1:10a drug simply alters that transmission. It just
- 1:13speeds things up or slows things down by increasing
- 1:17or decreasing the activation of receptors that
- 1:19are already sitting there. Doing their normal
- 1:21jobs. Exactly. Doing what they always do. Which
- 1:23means, and this is kind of a crazy philosophical
- 1:26thing to think about, If someone acts entirely
- 1:30quote -unquote out of character, the capacity
- 1:33for that behavior was already wired into their
- 1:36biology. Yeah, it was inside them the whole time.
- 1:38Right. If we're treating human biology like a
- 1:41car, the drug isn't like... a new steering wheel
- 1:44giving you a completely different direction.
- 1:45It is just a brick placed on the gas pedal. Or
- 1:48a slashed brake line. Yes, exactly. And that
- 1:51is exactly what we are unpacking today, figuring
- 1:53out how drugs actually do what they do to the
- 1:56body. And just to put this into context for you,
- 1:58our last deep dive into the source material was
- 2:00all about pharmacokinetics, right? The absorption
- 2:03stuff. Yeah, what your body does to a drug, how
- 2:05you absorb it, metabolize it, clear it out. But
- 2:08now we are flipping the script. Pharmacodynamics.
- 2:11Right. Pharmacodynamics is the study of what
- 2:13the drug does to you. And that BRCA on the gas
- 2:15pedal analogy holds up perfectly when we zoom
- 2:18all the way down to the synaptic scale. Down
- 2:21to the individual neurons. Exactly. You have
- 2:24these postsynaptic receptors on the receiving
- 2:26end of a synapse. When a drug alters transmission,
- 2:30it causes those specific receptors to open or
- 2:33close ion channels. And that creates the actual
- 2:36electrical changes, right? The excitatory and
- 2:39inhibitory potential. Yeah, the EPSPs and IPSPs.
- 2:42Right, right. So an excitatory postsynaptic potential
- 2:44makes a neuron more likely to fire. It pushes
- 2:47it toward action. Like the gas pedal. Yeah. And
- 2:50an inhibitory potential makes it less likely
- 2:52to fire. Right. And when you scale those tiny
- 2:54microscopic electrical shifts up to higher brain
- 2:57networks, you get massive behavioral changes.
- 3:00Right, like take your overall level of alertness.
- 3:03Oh, that's a perfect example. Because that is
- 3:04dictated by a network called the ascending reticular
- 3:07activating system or the ARS. So stimulant drugs
- 3:11like amphetamine, they don't conjure wakefulness
- 3:14out of the ether. They just dramatically increase
- 3:17neurotransmission in the ARS. And depressants
- 3:20like alcohol. alter transmitters to induce sedation.
- 3:24It's really all just turning pre -existing volume
- 3:26knobs up or down. But the notes highlight that
- 3:29it isn't just about the receiving end, the postsynaptic
- 3:32side. Right, the presynaptic neuron matters,
- 3:34too. Exactly. The sending neuron has its own
- 3:37modulators. It has receptors that control how
- 3:40much transmitter gets released into the gap in
- 3:42the first place. Yeah, the autoreceptors and
- 3:44heteroreceptors. Right. And I actually use this
- 3:47sort of like moral framework to memorize these
- 3:49two for the exam. How does that work? Well, so
- 3:52the first one is the auto receptor, which I think
- 3:55of as the moral conscience, or like the guilt
- 3:57of the neuron. Oh, I like that. Because it works
- 4:00as a negative feedback loop. Exactly. A primary
- 4:03neuron is firing, spitting out neurotransmitters
- 4:05into the synapse. But it has these auto receptors
- 4:08located on its own terminal, right near the release
- 4:11site. Right, so as the neurotransmitters fill
- 4:13the gap, some of them naturally drift back and
- 4:16hit the neuron's own autoreceptors. It sinks
- 4:19itself. Yeah, it's the conscience kicking in.
- 4:21The neuron senses its own output and says, OK,
- 4:24that's enough. We flooded the zone. Let's shut
- 4:25it down. It self -regulates. That's a great way
- 4:28to remember it. But then you have heteroreceptors.
- 4:30And the prefix hetero means different. So if
- 4:34autoreceptors are internal guilt, heteroreceptors
- 4:37are basically peer pressure. Peer pressure. because
- 4:40they are activated by neurotransmitters released
- 4:44from entirely different neighboring neurons.
- 4:46You have your primary neuron doing its job, and
- 4:49a completely separate neuron releases chemicals
- 4:51onto the primary neuron's hetero receptors. So
- 4:54it is literally an external influence like peer
- 4:57pressure, forcing the primary neuron to either
- 4:59ramp up its release or shut it down. Exactly.
- 5:02So a drug can target the postsynaptic side to
- 5:05change the receiving signal, or it can target
- 5:08these presynaptic conscience and peer pressure
- 5:10receptors to basically manipulate how the brain
- 5:13communicates behind the scenes. Okay, but how
- 5:15does a chemical physically interact with these
- 5:18receptors to actually make that happen? Because,
- 5:20I mean, I know we always hear the lock and key
- 5:22analogy in intra -psych, but the notes get way
- 5:25more specific than that. Oh yeah, we have to
- 5:27go much deeper. First we need to define ligands.
- 5:30Right. A ligand is essentially anything that
- 5:32binds to a receptor. So we have... endogenous
- 5:35ligands, which are naturally produced inside
- 5:38us. Like our own hormones and neurotransmitters.
- 5:40Exactly. And then we have exogenous ligands from
- 5:42outside the body, which are your pharmaceuticals
- 5:45or plant products. The drugs. Right. Now when
- 5:48a drug binds directly to a postsynaptic receptor
- 5:51and successfully activates it, it is called an
- 5:54agonist. And to be a true agonist, the drug needs
- 5:57two very distinct traits, right? Affinity and
- 6:00efficacy. Yes. So affinity is the physical attraction,
- 6:04is how well the key actually fits into the lock.
- 6:06Right, and efficacy is the ability to activate
- 6:08the receptor once it's inside. How well the key
- 6:11turns. Exactly. But even then, there's a whole
- 6:14spectrum to this. Take morphine, for example.
- 6:16It's a full agonist. It has incredibly high efficacy
- 6:19at opioid receptors. It turns the lock all the
- 6:22way. Yep. But then you have buprenorphine, which
- 6:25is a partial agonist. It has affinity for those
- 6:28exact same opioid receptors. It fits the lock,
- 6:31but it has reduced efficacy. So it only turns
- 6:33the lock halfway, giving a much weaker effect.
- 6:36Exactly. Which brings us to the complete opposite
- 6:39end of the spectrum. antagonists. Right, so if
- 6:42an agonist is a key that opens the door, an antagonist
- 6:46is basically a broken key jammed into the lock.
- 6:49That is the perfect way to visualize it. It has
- 6:52affinity, meaning it fits into the keyhole perfectly,
- 6:54but it has absolute zero efficacy. You cannot
- 6:57turn it. Because it's jammed in the lock, it
- 6:59physically blocks the real key, the endogenous
- 7:02neurotransmitter, from getting inside. It's just
- 7:04a receptor blocker. doing nothing but denying
- 7:06access. And there's actually a turf war happening
- 7:09here, depending on the type of antagonist. Oh,
- 7:11right. The competitive versus non -competitive
- 7:12ones? Yeah. So competitive antagonists are fighting
- 7:15the natural neurotransmitter for the exact same
- 7:18active site. And that competition means the antagonist
- 7:21can eventually be overpowered, right? Yes. If
- 7:24the brain is flooded with a massive surge of
- 7:26the natural neurotransmitter, the sheer numbers
- 7:29will literally just... crowd out the competitive
- 7:32antagonist, and restore normal biological function.
- 7:35Just by outnumbering it. Exactly. But non -competitive
- 7:39antagonists operate completely differently. They
- 7:42either bind irreversibly to the active site,
- 7:45meaning they just refuse to let go no matter
- 7:46what, or they bind to a completely different
- 7:49site on the receptor. And in both scenarios,
- 7:51flooding the brain with more agonist doesn't
- 7:53help at all. Nope. The system is just jammed.
- 7:56Well, and speaking of binding to a completely
- 7:58different site, that brings us to allosteric
- 8:01modulators. Oh, these are fascinating. Yeah.
- 8:03Because the Greek root allos means other, and
- 8:06stereos means shape. So these drugs bind to an
- 8:10other site, not the main active site, and they
- 8:12actually physically change the shape of the entire
- 8:15receptor protein. It's so cool. It is. If we
- 8:19stick to the door analogy, it's like a carpenter
- 8:21coming in and warping the door frame. Yes. A
- 8:23positive allosteric modulator warps the frame
- 8:26so that the normal key suddenly fits perfectly
- 8:29and turns with practically zero effort. Like
- 8:32caffeine and benzodiazepines do this. They make
- 8:35the natural transmitters work significantly better.
- 8:37Right. And a negative modulator warps the frame
- 8:40so badly that the real key won't even go in at
- 8:42all. And you know, we actually have to push this
- 8:44locking key analogy even further when we look
- 8:47at inverse agonists. Wait, inverse agonists?
- 8:50Yeah. Because for decades, the assumption in
- 8:52the field was that a receptor was either simply
- 8:54on or off. But we now know receptors have a basal
- 8:59resting level of activity. They're always humming
- 9:01a little bit in the background. Exactly. A full
- 9:03agonist turns that hum into a roar. An antagonist
- 9:07just blocks the roar, keeping the receptor humming
- 9:10at its baseline. But an inverse agonist actively
- 9:13suppresses that hum, right? It forces the receptor's
- 9:16activity below its normal resting baseline. The
- 9:18notes use benzodiazepines as an example here
- 9:21again. A normal benzodiazepine agonist enhances
- 9:24receptor activity to reduce anxiety. But if you
- 9:28take a benzodiazepine inverse agonist, it pushes
- 9:31the receptor activity into a negative state,
- 9:33which actively induces severe anxiety and even
- 9:36convulsions. It's wild that a receptor can be
- 9:38driven into the exact opposite of its intended
- 9:41function. It totally is. And it really reveals
- 9:43the incredible mechanical complexity of these
- 9:46systems. Plus, up until now, we've only really
- 9:48discussed direct action. Drugs physically touching
- 9:51the postsynaptic receptors. Right. But indirect
- 9:54action can achieve massive physiological changes
- 9:57without the drug ever interacting with that main
- 9:59lock. And I actually found another moral analogy
- 10:02to help remember one of these indirect mechanisms
- 10:04for the exam. Let's hear it. Let's look at reuptake
- 10:07inhibitors like cocaine or therapeutic SSRI selective
- 10:13serotonin reuptake inhibitors. Normally, a neuron
- 10:16releases transmitters to send a message and then
- 10:18it uses transporter proteins to efficiently vacuum
- 10:21them back up and recycle them. It cleans up the
- 10:23synapse. Exactly. But a reuptake inhibitor blocks
- 10:27those transporters. So I memorize this as the
- 10:30sin of greed. The sin of greed. Yeah. The drug
- 10:33stops the brain from sharing and recycling. It
- 10:36greedily hoards the neurotransmitter in the synaptic
- 10:39cleft, forcing it to just sit there and relentlessly
- 10:42hammer the postsynaptic receptors over and over.
- 10:46That is a brilliant way to picture it. Hoarding
- 10:48the chemical in the gap forces a massive over
- 10:51-activation of the system without the drug itself
- 10:53ever touching the receiving neuron. It's so efficient.
- 10:57It really is. Another indirect mechanism is a
- 11:00releasing agent. Amphetamines fall into this
- 11:02category. Right. They literally force the presynaptic
- 11:04neuron to dump enormous, unnatural amounts of
- 11:08its own neurotransmitters into the synapse. And
- 11:10if a drug isn't forcing release or hoarding the
- 11:12chemicals, it might just be killing the cleanup
- 11:14crew. The enzymes. Right. Enzyme inhibitors like
- 11:16MAOI. which are those older antidepressants,
- 11:19they literally stop enzymes from breaking down
- 11:21the transmitter. So the neurotransmitters just
- 11:23pile up, leading to the exact same result. Increased
- 11:26receptor activation. And, you know, all of these
- 11:29mechanisms, the direct, indirect agonists, inhibitors,
- 11:34they describe what a single chemical does in
- 11:36total isolation. Which is almost never how it
- 11:39actually happens in the real world. Exactly.
- 11:41The reality is that humans frequently mix substances,
- 11:45which introduces the math of drug interactions.
- 11:49When multiple chemicals hit these receptors simultaneously,
- 11:52the results are highly quantifiable. Well, the
- 11:54simplest one is additive, right? Just one plus
- 11:56one equals two. Yep. If drug A gives you one
- 11:59unit of effect and drug B gives you one unit,
- 12:02taking them together just stacks unpredictably,
- 12:04you get two units. But the danger really emerges
- 12:07when they are synergistic. Yes, that means they
- 12:10multiply each other. So drug A might be a 2 and
- 12:12drug B is a 4. Together they don't make 6, they
- 12:15make like... 10 or 20. Exactly. Mixing ethanol
- 12:18with a sedative drug is a classic synergistic
- 12:21interaction. Oh, wait. Both depressed neuronal
- 12:23activity but combining them multiplies that suppression,
- 12:27which often leads straight to respiratory failure.
- 12:29It's so dangerous. Then there is potentiation,
- 12:32which the textbook also calls permissive. Yes,
- 12:34permissive. This happens when one drug basically
- 12:37does nothing on its own, but its mere presence
- 12:41heavily enhances a second drug. It basically
- 12:44permits the second drug to hit much, much harder.
- 12:47And finally, you have antagonism, which is mathematical
- 12:50subtraction. The obvious example here is naloxone.
- 12:53Oh, the opioid reversal drug. Exactly. Naloxone
- 12:56is a competitive opioid antagonist. During a
- 12:59life -threatening overdose, a person's respiratory
- 13:02system shuts down because opioids are fully agonizing
- 13:05those receptors. Right. But administering a loxone
- 13:08floods the brain, violently ripping the opioids
- 13:11off the receptors because it competes for the
- 13:13exact same active site. It subtracts the drug's
- 13:16effect and reduces the respiratory failure almost
- 13:19instantly. That is just incredible. But if we
- 13:22can quantify all this addition, multiplication,
- 13:24and subtraction, how do pharmacologists actually
- 13:27map it all out? We have to talk about the dose
- 13:29-response curve. Oh, yes. Because if you're taking
- 13:31this class, you are going to be staring at this
- 13:33specific graph constantly. Constantly. To understand
- 13:37how much of a drug is required to achieve a specific
- 13:39effect, you plot it out. The x -axis is the dose
- 13:43of the drug, and the y -axis is the intensity
- 13:45of the response, usually going from 0 to 100
- 13:47percent. Right. But the defining feature of this
- 13:50graph is that the x -axis uses a logarithmic
- 13:53scale. Because drug doses range from microscopic
- 13:56like 0 .01 milligrams all the way up to hundreds
- 14:00of milligrams. It's a huge range. Yeah. If we
- 14:03plotted that on a standard linear graph, the
- 14:05piece of paper would have to be, like, miles
- 14:07long. Exactly. So logging the x -axis going from
- 14:100 .01 to 0 .1 to 1 to 10 compresses that massive
- 14:13range into a single readable page. And that logarithmic
- 14:16compression transforms what would be a sprawling
- 14:19hyperbolic shape into a tight symmetrical S -curve,
- 14:23a sigmoidal curve. A classic S -curve. Right.
- 14:25At the very bottom left, at minuscule doses,
- 14:28Practically nothing happens. Then you hit the
- 14:30threshold dose. The absolute lowest dose that
- 14:32produces any measurable physiological response.
- 14:35Exactly. And right after that, the curve shoots
- 14:38upward steeply. A tiny increase in dose suddenly
- 14:41yields a massive spike in effect. Eventually
- 14:44it tapers off horizontally at the top, forming
- 14:47the top hook of the S. And that flat line at
- 14:49the top is the ceiling effect. Giving a patient
- 14:51more of the drug at that point is completely
- 14:53useless because every single available receptor
- 14:56is already occupied. Yeah, just wasting medicine.
- 14:58Right. Though as we map these out... alcohol
- 15:01actually throws a huge wrench into the clean
- 15:04S -curve model. It really does. Alcohol requires
- 15:07a biphasic curve. Bi meaning two, phasic meaning
- 15:11phases. Because at a lower dose, alcohol triggers
- 15:14a stimulating effect, you know, the buzz. That
- 15:16is phase one. Right. But as the dose increases
- 15:19along the x -axis, the physiological response
- 15:21completely flips. It crosses into phase two,
- 15:24becoming heavily depressive. It's definitely
- 15:26not a single trajectory like most pharmaceuticals.
- 15:28But for those standard drugs that follow the
- 15:31S -curve, the absolute most critical data point.
- 15:33is the ED50, the effective dose 50. Okay, yes.
- 15:37The ED50 represents the exact dose required to
- 15:40produce half or 50 % of that specific drug's
- 15:44maximum possible response. Finding this median
- 15:47point is how pharmacologists compare different
- 15:50drugs to determine their potency and their efficacy.
- 15:52Okay, wait, I need to stop you here. Sure, what's
- 15:54up? Because I am genuinely confused by this,
- 15:57and I keep getting this wrong on the practice
- 15:58quizzes. It is honestly the most common point
- 16:01of confusion in the entire chapter. Good. It's
- 16:03not just me. Because if a drug is incredibly
- 16:06potent like fentanyl compared to standard morphine,
- 16:09shouldn't that automatically mean it has a massive
- 16:12effect? Not necessarily. Why do pharmacologists
- 16:14treat potency and efficacy as two completely
- 16:16separate concepts? I just don't get why they
- 16:18are grafted differently. So let's just isolate
- 16:21the axes on the graph. Potency is exclusively
- 16:24about the x -axis, the horizontal line, measuring
- 16:27the physical amount of the drug. If a drug is
- 16:30highly potent, its S -curve sits very far to
- 16:33the left on the graph. It just means you only
- 16:35need a microscopic crumb of the substance to
- 16:38reach that ED50. But efficacy is exclusively
- 16:42about the age axis, the vertical line measuring
- 16:45the intensity of the response. OK, so potency
- 16:48is just how much powder is on the scale. Efficacy
- 16:51is how high the line travels up the graph before
- 16:54hitting its ceiling. Exactly. Think back to buprenorphine,
- 16:57the partial agonist we talked about. Oh, right.
- 17:00It is highly potent. You only need a tiny milligram
- 17:03dose to trigger a response, so its curve starts
- 17:06very far to the left. Right. But because it's
- 17:09only a partial agonist, its efficacy is low.
- 17:11The curve hits its ceiling and flattens out halfway
- 17:14up the axis. Morphine requires a much larger
- 17:17dose, making it less potent, but its efficacy
- 17:20climbs all the way up to 100%. Okay, that makes
- 17:23sense. A highly potent drug doesn't necessarily
- 17:25throw the hardest punch, it just means it takes
- 17:28very little effort to throw whatever punch it
- 17:30has. That is the perfect way to summarize it.
- 17:32Wow, that finally clicks. Potency is the amount
- 17:34required, efficacy is the maximum punch. But,
- 17:37you know, knowing a drug's maximum punch forces
- 17:40us to look at the darker side of this science.
- 17:42Yeah, the safety side. Right. Because knowing
- 17:44how to achieve a peak high or completely eliminate
- 17:47pain is fascinating. But how do doctors actually
- 17:50know a specific dose won't just straight up kill
- 17:53a patient? That is where pharmacology intersects
- 17:55with moral responsibility. Right. To measure
- 17:57safety, we have to abandon the single -subject
- 18:00S -curve and look at population curves. Instead
- 18:04of measuring the intensity of a drug's effect
- 18:06in one person, a population curve measures the
- 18:08percentage of people who show a specific desired
- 18:11effect at a given dose. So the definition of
- 18:14ED50 completely changes here. It does. It no
- 18:17longer means half the maximum effect. On a population
- 18:20curve, ED50 is the dose that is therapeutically
- 18:23effective for 50 % of the people who take it.
- 18:25Right. And immediately to the right of that effective
- 18:28curve, pharmacologists plot the toxic curve.
- 18:30The dangerous one? Yeah. They calculate the TD50,
- 18:33the dose that proves toxic for 50 % of the population,
- 18:36and the LD50, the lethal dose, for 50%. The physical
- 18:39distance on the graph between the effective curve
- 18:41and the toxic curve is known as the therapeutic
- 18:43window. And you want that window to be massive.
- 18:45Right. Huge. You quantify that safety margin
- 18:49using the therapeutic index, or TI. You simply
- 18:52divide the toxic dose, the TD50, by the effective
- 18:56dose, the ED50. A higher number means a wider
- 18:59gap between healing and harm. Which is good.
- 19:02Yes. A small TI means the dose that cures you
- 19:05is terrifyingly close to the dose that poisons
- 19:08you. Hold on. I actually have a massive problem
- 19:11with the therapeutic index, and the notes highlight
- 19:13this as a serious ethical flaw too. Oh, about
- 19:16the slopes. Yes. The TI formula only uses those
- 19:19median 50 % points. It completely ignores the
- 19:22actual slope of the lines on the graph. It does.
- 19:25And ignoring the slope creates a really dangerous
- 19:27blind spot in clinical practice. Right. Think
- 19:29about the moral hazard here. different drugs
- 19:31with the exact same therapeutic index score.
- 19:35But if the slopes of their curves are shallow
- 19:36and wide, the bottom tail of the toxic curve
- 19:39might actually cross over and overlap with the
- 19:41top tail of the effective curve. Which is a nightmare.
- 19:44Right. And doctors don't prescribe an ED50. No
- 19:47doctor looks at a patient and says, here's a
- 19:49dose that only works half the time. No, they
- 19:51prescribe maximal heavy doses to ensure 100 %
- 19:54of their patients get relief. Exactly. So if
- 19:57those curves overlap, giving a strong therapeutic
- 20:00dose to patient A might accidentally cross the
- 20:02threshold into the toxic zone for patient B,
- 20:05relying on the TI just feels like playing Russian
- 20:08roulette with a prescription pad. Which is exactly
- 20:10why relying solely on the therapeutic index is
- 20:13considered outdated for real -world application.
- 20:16To eliminate that overlap, pharmacologists use
- 20:19a far more rigorous metric called the Certain
- 20:21Safety Index, or CSI. Some textbooks also refer
- 20:24to it as the margin of safety. And how does the
- 20:27CSI fix the math? It just abandons the 50 percent
- 20:30marks entirely. The CSI takes the TD1, the minimum
- 20:33dose that causes toxicity in just one percent
- 20:36of the population, and divides it by the ED99.
- 20:39The dose that is therapeutically effective for
- 20:4199 percent of the population. Exactly. I absolutely
- 20:43love the CSI because it feels like pure utilitarian
- 20:46moral calculus. It really is. It mathematically
- 20:49demands that you almost guarantee healing like
- 20:5199 percent of people get the relief they need
- 20:54while demanding The risk of harm drops to practically
- 20:57zero. By using the extreme ends of the data,
- 21:00it completely accounts for the slopes and ensures
- 21:03there is no hidden overlapping danger. It represents
- 21:06the true gold standard for clinical drug safety.
- 21:09And honestly, when you step back and look at
- 21:11the progression of this entire chapter, it really
- 21:13is a remarkable sequence. It is. We started at
- 21:16the microscopic level, looking at how drugs bind
- 21:19to postsynaptic receptors or manipulate presynaptic
- 21:23release through indirect mechanisms like reuptake
- 21:26inhibition. Right. Then we saw how those interactions
- 21:28compound mathematically when they're mixed together.
- 21:31We learned to graph potency against efficacy
- 21:33using logarithmic S -curves, and we concluded
- 21:36with a life or death population math required
- 21:38to ensure these chemicals heal rather than harm.
- 21:41It is a lot of dense material to process for
- 21:44one exam, but once you understand it, it fundamentally
- 21:47changes how you look at a simple pill bottle.
- 21:49It really does. And, you know, it leaves me with
- 21:51one final lingering thought for you to chew on
- 21:54before we wrap up this study session. Let's hear
- 21:56it. If pharmacodynamics proves that every high,
- 22:00every crash, and every miraculous therapeutic
- 22:02rescue is ultimately just a mathematical alteration
- 22:06of our pre -existing biology, then where exactly
- 22:10is the line between our authentic selves and
- 22:12the chemistry we consume? That is a deep question.
- 22:15It is. Next time you take even just a sip of
- 22:18coffee to wake up or a headache pill to focus,
- 22:21ask yourself... Is the drug changing you into
- 22:24someone else or is it just revealing a faster,
- 22:27louder, or maybe quieter version of what was
- 22:29already sitting there inside you? That profound
- 22:32question is honestly the true foundation of psychopharmacology.
- 22:35It really is. Thank you for joining us for this
- 22:37session of The Psychology Undergrad. Keep reviewing
- 22:39those notes, keep analyzing those curves, and
- 22:42as always, keep questioning everything.